ClinicalTrials.gg
RecruitingNCT05932589Updated Oct 26, 2026

Neurophysiologic Biomarkers in Rett Syndrome

An observational study in Rett Syndrome, RTT and Rett Syndrome, Atypical, sponsored by Children's Hospital of Philadelphia. Recruiting at 6 sites in United States. Open to female participants aged 1 Year to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Children's Hospital of Philadelphia · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Updated Oct 26, 2026Enrollment updatedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
222
Ages
1 Year to 18 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.

Planned enrollment
10th of 21
222 · median 146
Started
2023
with 6 others
Observational
21 of 55
6 open now
Primary completion
2028-03
later than 13 of 20 live
Registered
40th of 55
by date

Among the 55 studies in Rett Syndrome with a site in United States, this one is the 10th largest by planned enrollment of the 21 observational ones that give a count, is one of 7 that started in 2023, is one of 21 observational ones, reaches primary completion later than 13 of the 20 other live ones, and was the 40th registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 1 Year to 18 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Rett Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to identify candidate biomarkers in individuals with Rett Syndrome (RTT). The main questions it aims to answer are:

  • Do these biomarkers change during clinical changes in individuals with RTT?
  • Are biomarkers stable over time in clinically stable individuals?
  • Do these biomarkers correlate with severity of RTT?

Participants will be asked to undergo an electroencephalogram (EEG) with measurements of Evoked Potentials (EP) to measure electrical activity in the brain.

Researchers will compare findings in individuals with RTT to those in typically developing individuals to see if there are differences between the two groups.

Read the detailed description

The main goal of the project is to identify potential biomarkers that can become measures for intervention and other translational studies and, at the same time, provide insight into abnormal synaptic activity and pathogenesis of RTT. Therefore, the proposed assessments will be performed with females with RTT and age matched typically developing females. These electrophysiological assessments will be compared to established clinical outcome measures from previous work in the NIH funded Rett and Rett related disorders natural history study. The neurophysiological parameters for RTT will be correlated with each other and also to disease staging, overall clinical severity scores and through exploratory analyses with specific clinical features. The investigators will also be testing procedures to perform the recordings, electrode types and placement, and ways to reduce movement and artifact within the data to establish best practices.

03

Conditions studied

  • Rett Syndrome
  • RTT
  • Rett Syndrome, Atypical

Browse trials for

Keywords

  • Biomarker
  • EEG
  • Evoked Potentials
  • MECP2
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
1 Year to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Enrolled participants with Rett syndrome will include individuals receiving clinical care through the Rett Syndrome clinics at participating sites. Typically developing individuals will be recruited using study recruitment centers or family members of Rett participants at each site. Each of the sites are International Rett Syndrome Foundation Centers of Excellence (Rettsyndrome.org).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Rett Group: Females ages 3-18 (inclusive) with a clinical diagnosis of RTT with a likely pathogenic or known pathogenic variant in MECP2.
  2. Likely Rett Group: Females from 1 year to \< 5 years of age with MECP2 variant if regression has not yet occurred or child is within 6 months of last skill loss.
  3. Typically developing (TD) Group: Females age matched to RTT population (1-18) with no developmental or cognitive concerns as assessed using the Child/Adult Behavioral Checklist, Survey of Well-Being of Young Children (\<5yo), or the Wide Range Achievement Test-4 (>5 yo).

Exclusion criteria

Exclusion Criteria:

Rett and Likely Rett Groups:

  1. Presence of a duplication in MECP2 or any other identified pathogenic variant in another gene with a neurodevelopmental phenotype.
  2. Active medical conditions not typically found in RTT.

Typically Developing Group:

  1. Score below norms on the performance tests
  2. Have a known neurological disorder (excluding migraine)
  3. Being on neuroactive medications.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
222 participants (estimated)
Patient registry
No

Groups and cohorts

  • RTT Females

    Females with Rett Syndrome

    Other: EEG and Auditory and Visual Evoked Potentials (AEP and VEP) · Other: Clinical assessment

  • Controls

    Females with typical development

    Other: EEG and Auditory and Visual Evoked Potentials (AEP and VEP)

Interventions

  • OtherEEG and Auditory and Visual Evoked Potentials (AEP and VEP)

    Through up to eight standardized sessions, participants will undergo AEP and VEP, as well as resting state EEG.

  • OtherClinical assessment

    Established clinical measures for RTT will be collected for RTT participants

06

What researchers measure

Primary outcomes

  1. Auditory Evoked Potential (AEP) latency (ms)

    Calculated N1, P1 latencies in Cz and other electrodes \[posterior temporal region (T5/P3/T3) electrodes\], will be used for analysis.

    Time frame: 5 years

  2. Auditory Evoked Potential (AEP) amplitude

    Amplitude of P1, P2 and N1 peaks (uV)

    Time frame: 5 years

  3. Visual Evoked Potential (VEP) latencies (ms)

    The latencies of the N1, P1, and N2 components will be identified primarily at occipital electrodes with Oz will be the primary electrode of analysis. N1-P1 time will be analyzed.

    Time frame: 5 years

  4. Visual Evoked Potential (VEP) amplitude

    N1-P1 amplitude at Oz and other occipital electrodes will be calculated.

    Time frame: 5 years

  5. EEG Analysis

    EEG Root mean square (RMS) amplitude, Amplitude variability, 1/f constant, power bands in typical bands (Delta, theta, alpha, Beta, gamma) and ratios will be calculated.

    Time frame: 5 years

Secondary outcomes

  1. AEP spectral analysis, dipole determination and spatial distribution

    spectral analysis of the individual waveforms, dipole determination of N1 and P1 peaks and spatial distribution of peak values.

    Time frame: 5 years

  2. VEP spectral analysis, dipole determination and spatial distribution

    spectral analysis of the individual waveforms, dipole determination of N1 and P1 peaks and spatial distribution of peak values.

    Time frame: 5 years

07

Study locations

6 of 6 sites recruiting
08

References and documents

Publications

  • Saby JN, Peters SU, Roberts TPL, Nelson CA, Marsh ED. Evoked Potentials and EEG Analysis in Rett Syndrome and Related Developmental Encephalopathies: Towards a Biomarker for Translational Research. Front Integr Neurosci. 2020 May 28;14:30. doi: 10.3389/fnint.2020.00030. eCollection 2020. PubMed 32547374 ↗
  • Saby JN, Benke TA, Peters SU, Standridge SM, Matsuzaki J, Cutri-French C, Swanson LC, Lieberman DN, Key AP, Percy AK, Neul JL, Nelson CA, Roberts TPL, Marsh ED. Multisite Study of Evoked Potentials in Rett Syndrome. Ann Neurol. 2021 Apr;89(4):790-802. doi: 10.1002/ana.26029. Epub 2021 Feb 4. PubMed 33480039 ↗
  • LeBlanc JJ, DeGregorio G, Centofante E, Vogel-Farley VK, Barnes K, Kaufmann WE, Fagiolini M, Nelson CA. Visual evoked potentials detect cortical processing deficits in Rett syndrome. Ann Neurol. 2015 Nov;78(5):775-86. doi: 10.1002/ana.24513. Epub 2015 Sep 18. PubMed 26332183 ↗

Individual participant data

Plan to share: Yes — The investigators intend to submit deidentified patient data into the National Database for Autism Research (NDAR) and database of Genotypes and Phenotypes (dbGaP). Study protocols and data analysis methods will be shared through future publications.

Time frame: Available data from this observational study will be released to the repository and will become available to the scientific community one year after publication of planned analyses, or after a period of 5 years from the date when the data were collected, whichever comes first.

Access criteria: National Institute of Mental Health (NIMH) Data Archive (NDA) policy will govern access criteria.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Mar 2028, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 6, 2023
StartActual
Oct 11, 2023
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
202→222
Oct 26, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedPresence of a duplication in MECP2 or any other identified pathogenic mutationvariant in another gene with a neurodevelopmental phenotype.
Oct 26, 2026
Contact
Study contact changed: d•••@chop.edu · •••1719→d•••@chop.edu · •••1719. See the current contact
Oct 26, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Children's Hospital of Los Angeles · Los Angeles, United StatesContact person changed (no phone or email listed)Contact removed (no phone or email listed)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Enrollment 202→222
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedPresence of a duplication in MECP2 or any other identified pathogenic mutationvariant in another gene with a neurodevelopmental phenotype.
    Contact Study contact changed: d•••@chop.edu · •••1719→d•••@chop.edu · •••1719. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Children's Hospital of Los Angeles · Los Angeles, United StatesContact person changed (no phone or email listed)Contact removed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05932589
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Oct 11, 2023
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Holly Dubbs, MS, CGC
Contact
dubbsh@chop.edu
215-590-1719
Eric Marsh, MD, PhD
principal investigator · Children's Hospital of Philadelphia
Jeffrey Neul, MD, PhD
principal investigator · Vanderbilt University Medical Cener

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion